

## Press Releases

# Boston Scientific to Establish New Global Headquarters in Marlborough Massachusetts

## **Company to Consolidate Natick, Mass. Headquarters into Existing Marlborough Site; Facility Expansion to Create Collaborative Campus Setting; Consolidation Expected to be Completed by Mid-Summer 2014**

Nov 8, 2012

Natick, Mass. (November 8, 2012) – Boston Scientific Corporation (NYSE:BSX) announces it will consolidate its Natick, Mass. global headquarters into its Marlborough, Mass. location, where a new global headquarters campus will be established.

The consolidation will occur in phases, commencing in the spring of 2013. The company anticipates employees will be essentially moved out of the Natick facility by mid-summer of 2014, when construction of an additional building on the Marlborough site is expected to be complete. Meanwhile, Boston Scientific is in final stages for Natick-based MathWorks to purchase the entire 500,000-square foot Natick facility, which it has occupied since 1995. Details of the arrangement are not being disclosed.

“A new global headquarters in Marlborough will more effectively support our long-term strategic plans,” said Mike Mahoney, president and chief executive officer of Boston Scientific. “Consolidating our Natick and Marlborough facilities is expected to foster greater collaboration and efficiency, benefitting our employees, our customers, and, ultimately, the patients they treat.”

The existing Marlborough facility, which Boston Scientific purchased in 2004, is known for its open and collaborative work environment. Additionally, the Marlborough buildings are LEED® (Leadership in Energy and Environmental Design) certified. LEED certification provides independent, third-party verification that the buildings are designed and built using strategies aimed at achieving high

performance in key areas of human and environmental health, including sustainable site development, water savings, energy efficiency, materials selection and indoor environmental quality.

The Marlborough facility is located near the intersection of Interstate 290 and Interstate 495. The Natick and Marlborough facilities are located approximately 13 miles apart. In addition to driving more effective collaboration and efficiency, the consolidation is expected to optimize the company's facilities and generate cost savings.

"The City of Marlborough is thrilled to be the new expanded home of Boston Scientific," said Arthur Vigeant, mayor, City of Marlborough. "The company has already been an outstanding corporate citizen and we look forward to having Boston Scientific play an even larger role in our community."

### **About Boston Scientific**

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit:

[www.bostonscientific.com](http://www.bostonscientific.com).

### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the disposition of our Natick facility, the construction of an additional facility on our Marlborough campus, and the timing and benefits of a consolidated headquarters. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.

As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

**CONTACT:**

Denise Kaigler

508-650-8330 (office)

Media Relations

Boston Scientific Corporation

[denise.kaigler@bsci.com](mailto:denise.kaigler@bsci.com)

Steven Campanini

508-652-5740 (office)

Media Relations

Boston Scientific Corporation

[steven.campanini@bsci.com](mailto:steven.campanini@bsci.com)

Sean Findlen

617-520-7268 (office)

Media Relations

Weber Shandwick

[sfindlen@webershandwick.com](mailto:sfindlen@webershandwick.com)

Michael Campbell

508-650-8023 (office)

Investor Relations

Boston Scientific Corporation

[investor\\_relations@bsci.com](mailto:investor_relations@bsci.com)

SOURCE Boston Scientific Corporation